<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066727</url>
  </required_header>
  <id_info>
    <org_study_id>GW002</org_study_id>
    <nct_id>NCT02066727</nct_id>
  </id_info>
  <brief_title>Lidocaine Combined Dexmedetomidine for Obturator Nerve Block</brief_title>
  <acronym>ONB</acronym>
  <official_title>Effects of Dexmedetomidine as an Adjuvant on the Medium Effective Concentration of Lidocaine for Obturator Nerve Block — A Perspective, Randomized，Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guolin Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Dexmedetomidine as an adjuvant of lidocaine can decrease the medium effective
      concentration(EC50) of lidocaine for obturator nerve block during transurethral resection of
      bladder tumor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A selective obturator nerve block(ONB) is an effective alternative to suppress the obturator
      nerve reflex which is  defined as a sudden, violent adductor muscle spasm when the obturator
      nerve  is stimulated directly by the electronic resector during transurethral resection of
      the tumor on the lateral bladder wall. Studies showed Dexmedetomidine as an adjuvant to LA
      prolongs peripheral nerve block duration without any nerve toxicity. In the following
      randomized, non-crossover study, the investigators test if Dexmedetomidine as an adjuvant
      can decrease the medium effective concentration(EC50) of lidocaine for obturator nerve block
      during transurethral resection of bladder tumor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of obturator nerve block</measure>
    <time_frame>15min</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>leg did not move at all during resection of the bladder tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication related with nerve block</measure>
    <time_frame>during operation, 0.5,24hour postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complication related with nerve block is defined as the presence of either bradycardia, delayed recovery, persistent groin pain, neuropathy during operation and postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline is administrated as an adjuvant of lidocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline is administrated as an adjuvant of lidocaine.</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects scheduled to undergo elective operation of TURBT on lateral wall for whom
             ONB was needed diagnosed through cystoscopy or CT examination preoperatively.

          2. Subject's American Society of Anesthesiologists physical status is I-II.

          3. The subject's parent/legally authorized guardian has given written informed consent
             to participate.

        Exclusion Criteria:

          1. Subject has a diagnosis of abnormal coagulation function.

          2. Subject has a diagnosis of Diabetes mellitus.

          3. Subject has a preexisting neurologic deficits of the lower extremities.

          4. Subject has a history of alcohol or drug abuse.

          5. Subject is pregnant or breast-feeding.

          6. Subject is obese (body mass index &gt;30kg/m2).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guolin Wang, MD.PHD</last_name>
    <role>Study Director</role>
    <affiliation>Tainjin Medical University General Hospita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuechun LU, MD</last_name>
    <phone>15902233666</phone>
    <email>luyuechun@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tainjin Medical University General Hospita&amp; the Second Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuechun LU, MD</last_name>
      <phone>15902233666</phone>
      <email>luyuechun@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yuechun LU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>February 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>Guolin Wang</investigator_full_name>
    <investigator_title>Tianjin Medical University General Hospital</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>obturator nerve block</keyword>
  <keyword>lidocaine</keyword>
  <keyword>EC50</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
